Dextech Medical Past Earnings Performance
Past criteria checks 0/6
Dextech Medical has been growing earnings at an average annual rate of 14.6%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 45.8% per year.
Key information
14.6%
Earnings growth rate
19.9%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | 45.8% |
Return on equity | -14.7% |
Net Margin | -83.3% |
Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Recent updates
Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans
Jan 10Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth
Sep 20We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate
Jun 03What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?
Feb 17Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth
Dec 12Revenue & Expenses BreakdownBeta
How Dextech Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 5 | -5 | 11 | 0 |
31 Dec 23 | 7 | -5 | 9 | 0 |
30 Sep 23 | 9 | -5 | 11 | 0 |
30 Jun 23 | 9 | -5 | 11 | 0 |
31 Mar 23 | 10 | -6 | 12 | 0 |
31 Dec 22 | 7 | -5 | 9 | 0 |
30 Sep 22 | 4 | -5 | 6 | 0 |
30 Jun 22 | 3 | -5 | 5 | 0 |
31 Mar 22 | 0 | -5 | 4 | 0 |
31 Dec 21 | 0 | -5 | 3 | 0 |
30 Sep 21 | 1 | -5 | 3 | 0 |
30 Jun 21 | 1 | -6 | 3 | 0 |
31 Mar 21 | 1 | -7 | 1 | 0 |
31 Dec 20 | 1 | -7 | 1 | 0 |
30 Sep 20 | 1 | -7 | 1 | 0 |
30 Jun 20 | 1 | -8 | 1 | 0 |
31 Mar 20 | 1 | -8 | 1 | 0 |
31 Dec 19 | 1 | -8 | 1 | 0 |
30 Sep 19 | 2 | -8 | 1 | 0 |
30 Jun 19 | 2 | -8 | 1 | 0 |
31 Mar 19 | 3 | -9 | 1 | 0 |
31 Dec 18 | 5 | -9 | 1 | 0 |
30 Sep 18 | 7 | -9 | 1 | 0 |
30 Jun 18 | 9 | -9 | 1 | 0 |
31 Mar 18 | 9 | -9 | 1 | 0 |
31 Dec 17 | 9 | -8 | 1 | 0 |
30 Sep 17 | 9 | -8 | 1 | 0 |
30 Jun 17 | 9 | -8 | 1 | 0 |
31 Mar 17 | 9 | -8 | 1 | 0 |
31 Dec 16 | 9 | -7 | 1 | 0 |
30 Sep 16 | 9 | -6 | 1 | 0 |
30 Jun 16 | 9 | -6 | 1 | 0 |
31 Mar 16 | 8 | -6 | 1 | 0 |
31 Dec 15 | 8 | -5 | 1 | 0 |
30 Sep 15 | 8 | -6 | 1 | 0 |
30 Jun 15 | 8 | -5 | 1 | 0 |
31 Mar 15 | 6 | -5 | 1 | 0 |
31 Dec 14 | 7 | -5 | 1 | 0 |
30 Sep 14 | 7 | -5 | 1 | 0 |
30 Jun 14 | 6 | -4 | 1 | 0 |
30 Jun 13 | 4 | -3 | 1 | 0 |
Quality Earnings: DEX is currently unprofitable.
Growing Profit Margin: DEX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DEX is unprofitable, but has reduced losses over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare DEX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DEX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: DEX has a negative Return on Equity (-14.65%), as it is currently unprofitable.